CN114793422A - 抗ctla-4单克隆抗体及其制备方法与应用 - Google Patents
抗ctla-4单克隆抗体及其制备方法与应用 Download PDFInfo
- Publication number
- CN114793422A CN114793422A CN202080086339.1A CN202080086339A CN114793422A CN 114793422 A CN114793422 A CN 114793422A CN 202080086339 A CN202080086339 A CN 202080086339A CN 114793422 A CN114793422 A CN 114793422A
- Authority
- CN
- China
- Prior art keywords
- antibody
- ctla
- seq
- sequence
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
抗CTLA‑4单克隆抗体及该抗体的制备和用途，抗CTLA‑4抗体具有毒性更低和活性更佳的优点；另外，抗CTLA‑4抗体还具有低含量的高甘露糖糖型和/或低含量的唾液酸化糖型，有助于延长抗体的半衰期和/或降低免疫原性。特别地，含有该抗体的制剂具有良好的稳定性。
Description
PCT国内申请，说明书已公开。
Claims (36)
- PCT国内申请，权利要求书已公开。
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911363904X | 2019-12-25 | ||
| CN201911363904.XA CN113024670A (zh) | 2019-12-25 | 2019-12-25 | Ctla-4抗体及其制备方法 |
| CN202010430026.5A CN113712906A (zh) | 2020-05-20 | 2020-05-20 | 抗ctla-4抗体制剂及其应用 |
| CN2020104300265 | 2020-05-20 | ||
| PCT/CN2020/139205 WO2021129775A1 (zh) | 2019-12-25 | 2020-12-25 | 抗ctla-4单克隆抗体及其制备方法与应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114793422A true CN114793422A (zh) | 2022-07-26 |
Family
ID=76573238
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202080086339.1A Pending CN114793422A (zh) | 2019-12-25 | 2020-12-25 | 抗ctla-4单克隆抗体及其制备方法与应用 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20230203164A1 (zh) |
| EP (1) | EP4082572A4 (zh) |
| CN (1) | CN114793422A (zh) |
| WO (1) | WO2021129775A1 (zh) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20220031843A1 (en) * | 2020-07-08 | 2022-02-03 | Regeneron Pharmaceuticals, Inc. | Stabilized Formulations Containing Anti-CTLA-4 Antibodies |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101193917A (zh) * | 2005-03-08 | 2008-06-04 | 法玛西雅厄普约翰有限责任公司 | 抗-MAdCAM抗体组合物 |
| AU2012200203B2 (en) * | 2005-03-08 | 2014-07-03 | Pfizer Products Inc. | Anti-CTLA-4 Antibody Compositions |
| AU2014240252B2 (en) * | 2005-03-08 | 2016-10-06 | Pfizer Products Inc | Anti-CTLA-4 Antibody Compositions |
| EP2340305A1 (en) * | 2008-09-26 | 2011-07-06 | Eureka Therapeutics, Inc. | Cell lines and proteins with variant glycosylation pattern |
| JP2020509037A (ja) * | 2017-02-28 | 2020-03-26 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | ワクチンに対する免疫応答を増強するための、ａｄｃｃが増強された抗ｃｔｌａ−４抗体の使用 |
| CN107881160A (zh) * | 2017-08-11 | 2018-04-06 | 百奥泰生物科技(广州)有限公司 | 一种由基因组被编辑的cho宿主细胞产生的具有独特糖谱的重组抗体及其制备方法 |
| CN107446050A (zh) * | 2017-08-11 | 2017-12-08 | 百奥泰生物科技(广州)有限公司 | Trop2阳性疾病治疗的化合物及方法 |
| CN107899020A (zh) * | 2017-08-11 | 2018-04-13 | 百奥泰生物科技(广州)有限公司 | Cd20阳性疾病治疗的化合物及方法 |
| WO2019152413A1 (en) * | 2018-02-02 | 2019-08-08 | Oncoimmune, Inc. | Methods of selecting and designing safer and more effective anti-ctla-4 antibodies for cancer therapy |
| MX2021007769A (es) * | 2018-12-26 | 2021-09-23 | Xilio Dev Inc | Proteínas de unión anti-ctla4 enmascaradas activables. |
| US20220193237A1 (en) * | 2019-04-18 | 2022-06-23 | Bristol-Myers Squibb Company | Ipilimumab variants with enhanced specificity for binding at low ph |
| WO2020249063A1 (en) * | 2019-06-13 | 2020-12-17 | Bio-Thera Solutions, Ltd. | Methods for the treatment of trop2 positive diseases |
-
2020
- 2020-12-25 CN CN202080086339.1A patent/CN114793422A/zh active Pending
- 2020-12-25 EP EP20907897.1A patent/EP4082572A4/en active Pending
- 2020-12-25 US US17/788,330 patent/US20230203164A1/en active Pending
- 2020-12-25 WO PCT/CN2020/139205 patent/WO2021129775A1/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20230203164A1 (en) | 2023-06-29 |
| EP4082572A1 (en) | 2022-11-02 |
| WO2021129775A1 (zh) | 2021-07-01 |
| EP4082572A4 (en) | 2024-03-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10493148B2 (en) | PD-1 agonist antibodies and uses thereof | |
| EP3344658B1 (en) | Antibodies specific to human t-cell immunoglobulin and itim domain (tigit) | |
| US8815237B2 (en) | Aglycosylated immunoglobulin mutants | |
| JP2022068296A (ja) | 抗ｃｄ１１２ｒ組成物及び方法 | |
| JP2020500016A (ja) | 活性化可能な抗ｃｔｌａ−４抗体およびその使用 | |
| KR20240029119A (ko) | 항-cd20/항-cd3 이중특이적 항체에 의한 치료를 위한 투약 | |
| WO2021000530A1 (zh) | 一种双特异性抗体及其制备方法与应用 | |
| EP2629798A2 (en) | Anti-folate receptor alpha antibody glycoforms | |
| US11753481B2 (en) | Bispecific antibodies against CEACAM5 and CD47 | |
| WO2021063350A1 (zh) | 一种融合蛋白及其应用 | |
| US20230365680A1 (en) | Combination therapy with anti-pvrig antibodies formulations, anti-tigit antibodies, and anti-pd-1 antibodies | |
| WO2021129775A1 (zh) | 抗ctla-4单克隆抗体及其制备方法与应用 | |
| CN113024670A (zh) | Ctla-4抗体及其制备方法 | |
| WO2022184067A1 (zh) | 抗tigit抗体在联合用药中的应用 | |
| CN115724986A (zh) | 三特异性抗体及其用途 | |
| KR20240021153A (ko) | Nkp46 및 cd38를 표적으로 하는 이중 특이적 항체 및 이의 사용 방법 | |
| US20200024347A1 (en) | Or10h1 antigen binding proteins and uses thereof | |
| WO2022184068A1 (zh) | 抗tigit抗体在治疗肿瘤或癌症中的应用 | |
| US20240082397A1 (en) | Anti-pvrig antibodies formulations and uses thereof | |
| US20240076373A1 (en) | Combination therapy with anti-pvrig antibodies formulations and anti-pd-1 antibodies | |
| EP4180457A1 (en) | Anti-cldn-18.2 antibody and use thereof | |
| WO2023098785A1 (zh) | 抗4-1bb抗体及其用途 | |
| WO2023134771A1 (zh) | 抗ctla-4抗体药物组合物及其用途 | |
| WO2023175614A1 (en) | Anti glucocorticoid-induced tnfr-related (gitr) protein antibodies and uses thereof | |
| WO2024044675A1 (en) | Methods of cancer treatment using anti-pd1 antibodies in combination with anti-tim3 antibodies |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |